New trends for osteoarthritis: Biomaterials, models and modeling

Manivong, Seng; Cullier, Aurélie; Audigié, Fabrice; Banquy, Xavier; Moldovan, Florina; Demoor, Magali; Roullin, V. Gaëlle

doi:10.1016/j.drudis.2023.103488

Cited by 16 publications

(14 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In particular, small diverse samples, rather than large scale robust studies that can enable definitive answers to important genetic and epigenetic correlates of osteoarthritis and what should its prevention look like, fail however to often situate the condition in the context of the local overall joint environment and forces acting or failing to act optimally on the joint. 17 Other reported perspectives include genetic based therapies and explanatory factors, [18][19][20] aspects of biomaterial development to treat osteoarthritis, 21,22 such as collagen chondro protection 23,24 and various lubricants 25 but few specifically account for the origin of the disease that is clearly quite diverse, 1 and may include vulnerability to excess stress as well as abnormal stress reactions that might be remediable, but may not be addressed by focal solutions or those that are not actionable or clearly understood. 26 In addition, biological cell based therapies that do not account for the overall environment of the damaged joint are also likely to prove suboptimal at best in clinical terms, no matter how carefully these are construed in the lab or tested on non-human samples.…”

Section: General Findingsmentioning

confidence: 99%

Osteoarthritis 2050 projections and its multiple mitigation challenges

Marks

2023

MOJGG

View full text Add to dashboard Cite

Osteoarthritis is increasingly being shown to be an immense costly public health problem among the older population that is not readily reversed. This brief examines 2023 data to establish what is being advanced to minimize the projected osteoarthritis burden and why this topic remains of great import. Using the key word: Older adults and Osteoarthritis the PUBMED, PubMed Central, and Google Scholar were explored for current 2023 articles of relevance. These data, while not all encompassing, reveal there is an urgent need to go beyond downstream surgical and narcotic remedies for ameliorating osteoarthritis pain and towards upstream preventive approaches, including the parallel role of health literacy and exercise interventions and their adherence. However, multiple challenges clearly prevail in this latter regard that warrant ongoing attention.

show abstract

Section: General Findingsmentioning

confidence: 99%

Osteoarthritis 2050 projections and its multiple mitigation challenges

Marks

2023

MOJGG

View full text Add to dashboard Cite

show abstract

“…This is the promising interest offered by hybrid functionalized hydro-expansive nanogels. These are true nanobiotechnology platforms made of a combination of biopolymers, used as drug delivery systems (DDSs) employed as carriers for bioactive molecules and administered directly into the joint (5)(6)(7). The selection and combination of bioactive molecules can be tailored to speci c therapeutic targets.…”

Section: Introductionmentioning

confidence: 99%

Blinded, Randomized Tolerance Study of a Biologically Enhanced Nanogel with Endothelin-1 and Bradykinin Receptor Antagonist Peptides via Intra-Articular Injection for Osteoarthritis Treatment in Horses

Terlinden,

Jacquet,

Manivong

et al. 2024

Preprint

Self Cite

View full text Add to dashboard Cite

Background: Osteoarthritis is a leading cause of pain and retirement in athletic horses. Hydro-expansive functionalized nanogels, acting as Drug Delivery Systems, constitute one of the current therapeutic prospects. These nanogels have the potential to combine mechanical benefits through polymers with the biological effect of prolonged release of bioactive molecules. The purpose of this double-blinded randomized tolerance study versus negative control was to evaluate the response of healthy joints to a single injection of the efficient dose and overdose of nanogels composed of chitosan and hyaluronic acid and featuring a type A endothelin receptor antagonist and a type B1 bradykinin receptor antagonist. The metacarpophalangeal joints of 8 healthy horses were randomly injected with 2.4 mL of functionalized nanogels and 2.4 mL of saline as control on the contralateral limb. Injections were repeated twice at one-week intervals, followed by injection of a triple dose of nanogel on week four. Clinical, ultrasonographic and synovial fluid cellular and biochemical follow-ups were performed up to three months following the first injection. Results: No change in general clinical parameters, lameness or sensitivity to passive flexion of the fetlocks was noted. Mild to moderate synovitis was noted on the day following injection in the treated group, with a significant difference (p < 0.05) compared to the control group. It spontaneously resolved on day 3 following the injections and did not increase with repeated injections. Similar effects were noted after injection of the triple dose but lasted for a week. Synovial fluid markers of inflammation also showed a transient significant increase in the treated group one week after each injection, but no differences were detected at the end of the study. Conclusions: Injections of the therapeutic dose of functionalized nanogel in healthy joints induced a mild transient inflammatory response in the joint. Three injections of the efficient dose at one-week intervals and injection of thrice the efficient dose induce a mildly greater inflammation without harmful effects on joints. Functionalized nanogels are well tolerated prospects for the treatment of osteoarthritis in horses. Their beneficial effects on arthritic joints have yet to be evaluated to determine their therapeutic potential.

show abstract

“…Except the aging and degeneration of the cartilage, sports-injury-caused instability of the joint would accelerate the progression of post-traumatic OA and OA of obesity [4]. Pain-modifying is the main management for early or middle stage OA, and joint replacement for end stage OA [5,6]. However, from early stage to end stage OA, most patients suffered pain and/or disability for more than ten years [5,6].…”

mentioning

confidence: 99%

“…Pain-modifying is the main management for early or middle stage OA, and joint replacement for end stage OA [5,6]. However, from early stage to end stage OA, most patients suffered pain and/or disability for more than ten years [5,6]. Therefore, clarifying the molecular mechanisms of OA and finding diseasemodifying therapeutic strategies for osteoarthritis is urgent and essential for OA treatment.…”

mentioning

confidence: 99%

“…Secondly, subchondral bone is the bedrock of joint cartilage and its remodeling plays a key role within pathogenesis and the progression of OA. As the junction of soft tissues and hard tissues, subchondral bone was identified as contributing to subchondral sclerosis, osteophytes formation and subchondral cysts formation [6][7][8]13]. Zhen et al identified that the activation of TGFβ signaling in subchondral bone initiated the pathological changes of OA [14].…”

mentioning

confidence: 99%

See 1 more Smart Citation